Pediatric toxic epidermal necrolysis treated successfully with infliximab

Lana Chafranska*, Ditte M Saunte, Nille Behrendt, Ulrikka Nygaard, Ryan J Christensen, Carsten Sand, Gregor B Jemec

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftArtikelForskningpeer review


Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults. We present a case of a 7-year-old boy with infection-associated TEN, diagnosed by typical clinical and histopathological features, most likely caused by Mycoplasma pneumoniae. Treatment with a single dose of infliximab 5 mg/kg intravenously on day 5 after the onset of symptoms was followed by cessation of all blister formation over 3 days and complete resolution within a week. Sequelae were mild, consisting of postinflammatory hyperpigmentation and dry eyes.

Sider (fra-til)342-345
Antal sider4
TidsskriftPediatric Dermatology
Udgave nummer3
StatusUdgivet - maj 2019

Bibliografisk note

� 2019 Wiley Periodicals, Inc.


Udforsk hvilke forskningsemner 'Pediatric toxic epidermal necrolysis treated successfully with infliximab' indeholder.